For example, in the SELECT trial (17,600 patients with cardiovascular disease and obesity but without T2D), weekly subcutaneous Semaglutide (2.4 mg) reduced the risk of major adverse cardiovascular events (MACE heart attack, stroke, or cardiovascular death) by 20% compared to placebo (HR 0.80
With its promising potential and the right support, Mounjaro could be a game-changer for those seeking to improve their health and quality of life
Prior authorization is common, but coverage itself is guaranteed
Noveltreat 0.5 mg Pre-filled Pen is a prescription medicine that belongs to a class called GLP-1 receptor agonists
FDA Approves Once-Weekly Wegovy Injection for the Treatment of Obesity in Teens Aged 12 Years and Older
Movement is key to good health and patients have reported that exercise becomes easier as they start losing weight